New study reveals Real-World impact of triple inhaler on COPD symptoms
NCT ID NCT06511193
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 35 times
Summary
This study follows 152 adults with COPD who start taking a three-in-one inhaler (budesonide/glycopyrronium/formoterol). Researchers measure changes in symptoms, quality of life, and lung attacks over 6 months. The goal is to see how well the treatment works in everyday life, not just in a lab.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Research Site
Windsor, Ontario, N8W 5V7, Canada
Conditions
Explore the condition pages connected to this study.